+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Emerging Market Outsourcing Report - Q3 2026

  • PDF Icon

    Report

  • 25 Pages
  • October 2026
  • Region: Global
  • GlobalData
  • ID: 6178658

Emerging Market Outsourcing Report - Q3 2026

Summary

This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q3 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and packaging (clinical and commercial) for countries in emerging markets.

Scope

This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:
  • CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
  • Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
  • Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.

Reasons to Buy

  • Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
  • Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
  • Learn about the past quarter’s M&A and financing deals in the manufacturing space.
  • Identify the latest contract service agreements.
  • Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
  • Stay ahead of disruption with updates on supply chain obstacles and new regulations.

Table of Contents

1 Industry Trends
1.1 India's pharma opportunity beyond the US
1.2 AstraZeneca adds biologics to its Chinese manufacturing expansion
1.3 China expands its manufacturing role for biopharma’s new drugs
2 Industry Analysis
2.1 Emerging market contract service agreements
2.2 Emerging market quarterly mergers, acquisitions, and financing - Q3 2026
3 Value Chain
3.1 API chemical
3.2 API biologics - protein and peptide
3.3 API biologics - cell, gene, vaccine, and virus therapies
3.4 Commercial dose manufacturing and packaging
3.5 Analytical Services
  • About the Authors
  • Contact Us
List of Tables
Table 1: Contract service agreements
Table 2: Mergers, acquisitions, and financing - Q3 2026
List of Figures
Figure 1: Number of FDA-approved innovator and biosimilar drugs manufactured in China
Figure 2: Contract service agreements by deal geography, by volume
Figure 3: Deals by deal geography, by volume: quarterly mergers, acquisitions, and financing
Figure 4: The contract manufacturing value chain

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • A1 Biochem Labs (India) Private Limited
  • Aarti Drugs Ltd
  • Alivus Life Sciences Ltd
  • Apitoria Pharma Pvt Ltd
  • Aragen Life Sciences Ltd
  • Asymchem Laboratories Tianjin Co Ltd
  • Ashland Inc
  • AstraZeneca
  • Auriga Research Pvt. Ltd.
  • Aurisco Pharmaceutical Co Ltd
  • Aurobindo Pharma Ltd
  • Axplora Group GmbH
  • Bajaj Healthcare Ltd
  • Bestchrom
  • Biodeal Pharmaceuticals Pvt Ltd
  • BioKangtai
  • Boehringer Ingelheim Pharmaceuticals
  • BratskKhimSintez
  • Caplin Point Laboratories Ltd
  • Capworks Investment Manager India Private Limited
  • Citeline
  • Cognizant
  • Cohance Lifesciences Ltd
  • Concord Biotech Ltd
  • Corona Remedies Ltd
  • Crystal Pharmatech Co Ltd
  • CSPC Pharmaceutical Group
  • CuraTeQ Biologics Pvt Ltd
  • Dr. Reddy's Laboratories Ltd
  • Esco Aster Bioengineering
  • Farmabios
  • Formycon AG
  • Fujian Genohope Biotechnology Co Ltd
  • Fusix Biotech Gmbh
  • Gland Pharma Ltd
  • GlobalData Plc
  • Gopaldas Visram & Co Ltd
  • GSK
  • Henkang Pharma
  • Hubei Gedian Humanwell Pharmaceutical Co Ltd
  • Indoco Remedies Ltd
  • Infinata
  • IPCA Laboratories Ltd
  • Jackson Laboratories Pvt Ltd
  • Jefferies
  • Jilin Asymchem Pharmaceuticals Co Ltd
  • Johnson & Johnson
  • Krebs Biochemicals & Industries Ltd
  • Maiva Pharma Pvt Ltd
  • Mergermarket
  • Morepen Laboratories Ltd
  • Neuland Laboratories Ltd
  • Novo AS
  • OneSource Specialty Pharma Ltd
  • Orchem Products
  • Pharmasyntez
  • Piramal Pharma Ltd
  • Porton Advanced Solution ltd
  • Qilu Pharmaceutical (Hainan) Co Ltd
  • Qilu Pharmaceutical Co Ltd
  • Recipharm Pharmaservice s Pvt Ltd
  • Renaissance Pharma Ltd
  • RMB Capitalworks
  • Sai Life Sciences
  • Santa Farma Ilac Sanayii AS
  • Shanghai Asymchem Biotechnology Co Ltd
  • Shantha Biologics Pvt Ltd
  • Sichuan Renan Pharmaceutical Co Ltd
  • Strides Pharma Science Ltd
  • Suzhou Hillhouse Qirui Medical Health Industry Investment Partnership
  • Viwit Pharmaceutical Co Ltd
  • Wanbury Ltd
  • WuXi AppTec Co Ltd
  • WuXi Biologics
  • Yapan Bio Pvt Ltd
  • Zhejiang Hengkang Pharmaceutical Co Ltd
  • 2Y-Biopharma Ltd